BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 35507413)

  • 1. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.
    Love C; Desai NB; Abraham T; Banks KP; Bodei L; Boike T; Brown RKJ; Bushnell DL; DeBlanche LE; Dominello MM; Francis T; Grady EC; Hobbs RF; Hope TA; Kempf JS; Pryma DA; Rule W; Savir-Baruch B; Sethi I; Subramaniam RM; Xiao Y; Schechter NR
    Am J Clin Oncol; 2022 Jun; 45(6):233-242. PubMed ID: 35507413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.
    Love C; Desai NB; Abraham T; Banks KP; Bodei L; Boike T; Brown RKJ; Bushnell DL; DeBlanche LE; Dominello MM; Francis T; Grady EC; Hobbs RF; Hope TA; Kempf JS; Pryma DA; Rule W; Savir-Baruch B; Sethi I; Subramaniam RM; Xiao Y; Schechter NR
    Clin Nucl Med; 2022 Jun; 47(6):503-511. PubMed ID: 35507433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ACR-ACNM-ARS-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radiopharmaceuticals.
    Wallner PE; Yoo DC; Calais J; Escorcia FE; Mari Aparici C; Michalski J; Morris M; Morris ZS; Pryma D; Rabatic BM; Sharma N; Vapiwala N; Ghesani MV; Subramaniam RM; Small W; Schechter NR
    Am J Clin Oncol; 2024 Apr; 47(4):169-176. PubMed ID: 38131352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACR-ABS-ACNM-ASTRO-SIR-SNMMI practice parameter for selective internal radiation therapy or radioembolization for treatment of liver malignancies.
    Hong K; Akinwande O; Bodei L; Chamarthy MR; Devlin PM; Elman S; Ganguli S; Kennedy AS; Koo SJ; Ouhib Z; Padia SA; Salem R; Selwyn RG; Yashar CM; Yoo DC; Zaki BI; Hartford AC; Trimmer CK
    Brachytherapy; 2021; 20(3):497-511. PubMed ID: 33824051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
    Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
    J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polish experience in Peptide receptor radionuclide therapy.
    Kunikowska J; Królicki L; Sowa-Staszczak A; Hubalewska-Dydejczyk A; Pawlak D; Mikolajczak R; Handkiewicz-Junak D; Szaluś N; Kamiński G; Cwikla J; Jakuciński M; Lukiewicz A; Kowalska A; Gut P
    Recent Results Cancer Res; 2013; 194():467-78. PubMed ID: 22918776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
    Harris PE; Zhernosekov K
    Front Endocrinol (Lausanne); 2022; 13():941832. PubMed ID: 36387893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lutetium-labelled peptides for therapy of neuroendocrine tumours.
    Kam BL; Teunissen JJ; Krenning EP; de Herder WW; Khan S; van Vliet EI; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1(Suppl 1):S103-12. PubMed ID: 22388631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging Advancements in Nuclear Medicine: Pancreatic Neuroendocrine Tumor Localization and Treatment.
    Stephens CP; Beam AS; Gray Z; Mansfield J; Reves L; Gray J; Stamey A; Collum M; Vijayakumar V
    Radiol Technol; 2022; 93(5):431-436. PubMed ID: 35508408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ACR-ACNM-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radium-223.
    Hurwitz M; Buscombe JR; Jacene HA; Klitzke AK; Lamonica D; Lu Y; Pryma DA; Rohren EM; Speer TW; Subramaniam RM; Thompson HM; Tomblyn MB; Wong WW; Xiao Y; Banks KP; Brown RKJ
    Am J Clin Oncol; 2020 Aug; 43(8):539-544. PubMed ID: 32520788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lutetium oxodotreotide (
    Smith-Palmer J; Leeuwenkamp OR; Virk J; Reed N
    BMC Cancer; 2021 Jan; 21(1):10. PubMed ID: 33402120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discordance Between Histopathologic Grading and Dual-Tracer PET/CT Findings in Metastatic NETs and Outcome of
    Adnan A; Basu S
    J Nucl Med Technol; 2022 Sep; 50(3):248-255. PubMed ID: 34876476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of peptide receptor radionuclide therapy (PRRT) in advanced metastatic bronchial neuroendocrine tumours (NETs).
    Mirvis E; Toumpanakis C; Mandair D; Gnanasegaran G; Caplin M; Navalkissoor S
    Lung Cancer; 2020 Dec; 150():70-75. PubMed ID: 33075738
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Hervás I; Bello P; Falgas M; Del Olmo MI; Torres I; Olivas C; Vera V; Oliván P; Yepes AM
    Rev Esp Med Nucl Imagen Mol; 2017; 36(2):91-98. PubMed ID: 27889527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematological Markers as Predictors of Treatment Outcomes with Lutetium 177 (
    Satapathy S; Bhattacharya A; Sood A; Kapoor R; Gupta R; Sood A; Sharma P; Khosla D; Mittal BR
    Cancer Biother Radiopharm; 2022 Feb; 37(1):23-29. PubMed ID: 34185573
    [No Abstract]   [Full Text] [Related]  

  • 16. Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant
    Parghane RV; Bhandare M; Chaudhari V; Ostwal V; Ramaswamy A; Talole S; Shrikhande SV; Basu S
    J Nucl Med; 2021 Nov; 62(11):1558-1563. PubMed ID: 33637590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
    Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
    Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors.
    Nicolini S; Bodei L; Bongiovanni A; Sansovini M; Grassi I; Ibrahim T; Monti M; Caroli P; Sarnelli A; Diano D; Di Iorio V; Grana CM; Cittanti C; Pieri F; Severi S; Paganelli G
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3260-3267. PubMed ID: 33604690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Analysis for Therapeutic Doses of Patients with Neuroendocrine Tumor Treated with Lutetium 177 (
    Kovan B; Özkan ZG; Demir B; Tunçman D; Işik EG; Şimşek DH; Büyükkaya F; Türkmen C; Şanli Y
    Cancer Biother Radiopharm; 2022 Feb; 37(1):17-22. PubMed ID: 34134512
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-effectiveness of Lutetium [
    Leeuwenkamp O; Smith-Palmer J; Ortiz R; Werner A; Valentine W; Blachier M; Walter T
    J Med Econ; 2020 Dec; 23(12):1534-1541. PubMed ID: 32990484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.